Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hetacillin is a semisynthetic beta-lactam antibiotic of the aminopenicillin family. It is a prodrug that itself has no antibacterial activity but is rapidly converted in the body to ampicillin, which exerts bactericidal effects by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Hetacillin was used for treating bacterial infections caused by susceptible organisms, primarily gram-positive bacteria. It was available for both human and veterinary use under various brand names but has been withdrawn from the market for human use due to lack of therapeutic advantage over ampicillin[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hetacillin.